Physician profile

Alberto B Caintic

Nephrology (Internal Medicine) · Tampa, FL

NPI 1679688006

$881.71

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$539.58

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $226.28 2019-2024 Farxiga
Bayer Healthcare Pharmaceuticals INC. $209.03 2021-2023
Mallinckrodt Hospital Products INC. $160.20 2023 Terlivaz
Amgen INC. $97.05 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $57.73 2019
Emergent Biosolutions INC. $56.96 2019
Novo Nordisk INC $43.07 2024 Rybelsus
Boehringer Ingelheim Pharmaceuticals, INC. $31.39 2023 Jardiance

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alberto B Caintic

$881.71

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/211697/alberto-b-caintic

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.